Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness
Author:
Publisher
Informa UK Limited
Link
http://www.tandfonline.com/doi/pdf/10.1517/14656566.2.4.623
Reference40 articles.
1. Regular review: Drug treatment of multiple sclerosis
2. Interferon beta in multiple sclerosis
3. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Neurology;2024-03-11
2. Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis;Journal of Internal Medicine;2020-12-20
3. Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review;FARM HOSP;2020
4. Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study;Degenerative Neurological and Neuromuscular Disease;2017-01
5. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator;The Lancet Neurology;2015-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.7亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2025 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3